These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34793285)

  • 1. Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective.
    Cojocaru E; Cojocaru C; Antoniu SA; Stafie CS; Rajnoveanu A; Rajnoveanu RM
    Expert Rev Respir Med; 2022 Mar; 16(3):257-261. PubMed ID: 34793285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19).
    McCarthy MW
    Expert Opin Pharmacother; 2022 Apr; 23(5):623-628. PubMed ID: 35103549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice.
    Crisan Dabija R; Antohe I; Trofor A; Antoniu SA
    Expert Rev Anti Infect Ther; 2021 Dec; 19(12):1553-1562. PubMed ID: 34015985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
    Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
    J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis.
    Baker JR; Mahdi M; Nicolau DV; Ramakrishnan S; Barnes PJ; Simpson JL; Cass SP; Russell REK; Donnelly LE; Bafadhel M
    Lancet Respir Med; 2022 Jun; 10(6):545-556. PubMed ID: 35397798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19.
    Liu Q; Chi S; Dmytruk K; Dmytruk O; Tan S
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon lambda as a potential treatment for COVID-19.
    McCarthy MW
    Expert Opin Biol Ther; 2023 May; 23(5):389-394. PubMed ID: 37147857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.
    Znaidia M; Demeret C; van der Werf S; Komarova AV
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters.
    Uraki R; Kiso M; Imai M; Yamayoshi S; Ito M; Fujisaki S; Takashita E; Ujie M; Furusawa Y; Yasuhara A; Iwatsuki-Horimoto K; Sakai-Tagawa Y; Watanabe S; Hasegawa H; Kawaoka Y
    Nat Microbiol; 2022 Aug; 7(8):1252-1258. PubMed ID: 35705860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study.
    He XL; Zhou YY; Fu W; Xue YE; Liang MY; Yang BH; Ma WL; Zhou Q; Chen L; Zhang JC; Wang XR
    Curr Med Sci; 2021 Dec; 41(6):1096-1104. PubMed ID: 34515914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b-Literature Review and Personal Preliminary Experience.
    Mary A; Hénaut L; Macq PY; Badoux L; Cappe A; Porée T; Eckes M; Dupont H; Brazier M
    Front Pharmacol; 2020; 11():592543. PubMed ID: 33329000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.
    Yu C; Kang L; Chen J; Zang N
    Int Immunopharmacol; 2020 Sep; 86():106740. PubMed ID: 32645630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Effect of Budesonide against SARS-CoV-2.
    Heinen N; Meister TL; Klöhn M; Steinmann E; Todt D; Pfaender S
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.